Literature DB >> 34433296

Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity.

Ayea El-Ghazali1, Sneha Deodhar1, Suzanne Saldanha1, Brooke Smyth1, Mark Izbrand2, Anamika Gangwar1, Mandana Pahlavani1, Anand Rohatgi1.   

Abstract

Objective: Cholesterol efflux capacity (CEC), the ability of extracellular acceptors to pick-up cholesterol from macrophages, is a clinically relevant cardiovascular biomarker. CEC is inversely associated with incident atherosclerotic cardiovascular disease events. However, CEC is only modestly associated with HDL-C (high-density lipoprotein cholesterol) levels, which may explain the failure of HDL-C raising therapies to improve atherosclerotic cardiovascular disease outcomes. Determinants of variation in CEC are not well understood. Thus, we sought to establish whether extreme high and low CEC is a robust persistent phenotype and to characterize associations with cholesterol, protein, and phospholipids across the particle size distribution. Approach and
Results: CEC was previously measured in 2924 participants enrolled in the Dallas Heart Study, a multi-ethnic population-based study from 2000 to 2002. We prospectively recruited those who were below the 10th and above 90th percentile of CEC. Our study revealed that extreme low and high CEC are persistent, robust phenotypes after 15 years of follow-up. Using size exclusion chromatography, CEC to fractionated plasma depleted of apolipoprotein B (fraction-specific CEC) demonstrated significant differences in CEC patterns between persistent high and low efflux groups. Fraction-specific CEC was correlated with fraction-specific total phospholipid but not apolipoprotein A-I, cholesterol, or total protein. These correlations varied across the size distribution and differed among persistent high versus low efflux groups. Conclusions: Extreme high and low CEC are persistent and robust phenotypes. CEC patterns in fractionated plasma reveal marked variation across the size distribution. Future studies are warranted to determine specific molecular species linked to CEC in a size-specific manner.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; cholesterol; foam cells; lipoproteins, HDL; phospholipids

Mesh:

Substances:

Year:  2021        PMID: 34433296      PMCID: PMC8458243          DOI: 10.1161/ATVBAHA.120.315648

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   10.514


  29 in total

Review 1.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

2.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

3.  HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population.

Authors:  Sanam Ebtehaj; Eke G Gruppen; Stephan J L Bakker; Robin P F Dullaart; Uwe J F Tietge
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-18       Impact factor: 8.311

4.  Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Olga V Demler; Steven J Adelman; Heidi L Collins; Robert J Glynn; Paul M Ridker; Daniel J Rader; Samia Mora
Journal:  Circulation       Date:  2017-04-27       Impact factor: 29.690

5.  Plasminogen promotes cholesterol efflux by the ABCA1 pathway.

Authors:  Nathalie Pamir; Patrick M Hutchins; Graziella E Ronsein; Hao Wei; Chongren Tang; Riku Das; Tomas Vaisar; Edward Plow; Volker Schuster; Marlys L Koschinsky; Catherine A Reardon; Richard Weinberg; David A Dichek; Santica Marcovina; Godfrey S Getz; Jay W Heinecke
Journal:  JCI Insight       Date:  2017-08-03

6.  Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease.

Authors:  Prahlad K Rao; Kate Merath; Eugene Drigalenko; Avinash Y L Jadhav; Richard A Komorowski; Matthew I Goldblatt; Anand Rohatgi; Mark A Sarzynski; Samer Gawrieh; Michael Olivier
Journal:  Clin Proteomics       Date:  2018-03-06       Impact factor: 3.988

7.  Apolipoprotein E particle size is increased in Alzheimer's disease.

Authors:  Thomas J Nelson; Abhik Sen
Journal:  Alzheimers Dement (Amst)       Date:  2018-11-13

8.  Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity.

Authors:  Andrea L Koekemoer; Veryan Codd; Nicholas G D Masca; Christopher P Nelson; Muntaser D Musameh; Bernhard M Kaess; Christian Hengstenberg; Daniel J Rader; Nilesh J Samani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-31       Impact factor: 8.311

Review 9.  High-Density Lipoproteins Are Bug Scavengers.

Authors:  Olivier Meilhac; Sébastien Tanaka; David Couret
Journal:  Biomolecules       Date:  2020-04-12

Review 10.  The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer's Disease.

Authors:  Dustin Chernick; Rui Zhong; Ling Li
Journal:  Biomolecules       Date:  2020-09-04
View more
  3 in total

Review 1.  Addressing dyslipidemic risk beyond LDL-cholesterol.

Authors:  Alan R Tall; David G Thomas; Ainara G Gonzalez-Cabodevilla; Ira J Goldberg
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

2.  Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.

Authors:  Damien Denimal; Sara Benanaya; Serge Monier; Isabelle Simoneau; Jean-Paul Pais de Barros; Wilfried Le Goff; Benjamin Bouillet; Bruno Vergès; Laurence Duvillard
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

Review 3.  The Role of High-Density Lipoprotein Cholesterol in 2022.

Authors:  Cesare R Sirtori; Alberto Corsini; Massimiliano Ruscica
Journal:  Curr Atheroscler Rep       Date:  2022-03-10       Impact factor: 5.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.